NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has agreed to work with MD Anderson spinout ApoCell to make its ApoStream liquid biopsy technology available to biotech and pharmaceutical companies.

ApoStream is a platform for the detection, isolation, and capture of circulating tumor cells (or other rare cells), and does not require the use of labels or antibodies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.